Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

INSANE: Sonnet shares surge as fda clears its first human trial for solid tumor candidate - The Real Truth

  • The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ:SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology. 
  • Sonnet will initiate its First-in-Human Phase 1 trial in adult oncology patients in Q2 of 2022. 
  • The study will establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) using monthly subcutaneous injections of SON-1010. 
  • The primary endpoint will assess the safety and tolerability of SON-1010, with key secondary endpoints planned to measure pharmacodynamics, pharmacodynamics, immunogenicity, and anti-tumor activity.
  • In August last year, Sonnet BioTherapeutics completed the discovery phase for its next preclinical pipeline candidate, SON-1410, its second bispecific compound integrating Interleukin 12.
  • The target indications for SON-1410 will be melanoma and renal cancers.
  • The company aims to file an IND in Q2 of 2022.
  • Price Action: SONN shares are up 84.6% at $0.51 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.